Multiple Myeloma Market shall be worth US$ 16.31 billion by 2030, according to Renub Research. Several factors contribute to the growth of the multiple myeloma market, including an aging population, advancements in treatment options, increased awareness a
28 Nov, 2023

A comprehensive industry analysis of the multiple myeloma market, including insights into market share, research on competitors and regions, and current advancements, has been recently released in a report by Renub Research titled "Multiple Myeloma Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis."

Multiple Myeloma Industry will grow at a CAGR of 6.04% from 2022 to 2030. The increasing prevalence of a multiple myeloma is assisting the rise of the multiple myeloma market. Cancer.Net predicts that in 2023, round 35,730 American adults could be diagnosed with multiple myeloma, with 19,860 being men and 15,870 being women. Unfortunately, the disease is anticipated to cause a predicted 12,590 deaths, with 7,000 men and five,590 ladies succumbing to it for the duration of the same year. The global growth in the older populace has further fueled the growth of the multiple myeloma market.

The upward push in government authorities’ initiatives and non-profit companies for treating blood cancers and multiple myeloma is anticipated to fuel the increase of the multiple myeloma market opportunity. In February 2023, the MMRF and the Lazarex Cancer Foundation joined forces to promote honest access to clinical trials for people with multiple myeloma cancers. This collaboration is anticipated to boom the demand for multiple myeloma treatments, contributing to the marketplace's boom.

In addition, in March 2022, the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s project philanthropy subsidiary, introduced an investment in TriumviraImmunologics (Triumvira), an Austin, TX-based clinical-stage biotech developing novel, targeted autologous and allogeneic T cellular immunotherapies that codecide the novel biology of T cells to deal with solid tumors and blood cancers.

For instance, in December 2022, Takeda is carrying out Phase I/ Phase II multicenter trials to investigate the safety, tolerability, efficacy, and immunogenicity of Modakafusp Alfa in patients with relapsed/refractory MM. The patients receiving 1.5 milligrams of Modakafusp Alfa each 4 weeks have shown a partial response or decrease in their cancer via over 50%. Thus, such development and corporation activities will in all likelihood increase the demand for MM treatment drugs, that is predicted to increase market growth in the upcoming years. Factors along with the growing burden of a multiple myeloma and the developing recognition on research and development to generate novel therapies and tablets for treating multiple myeloma are boosting the market increase.

The increasing burden of multiple myeloma is driving the demand for multiple myeloma treatment. For instance, as according to the statistics published through Cancer Australia, in August 2022, approximately 2,625 new instances of multiple myeloma (1,540 cases in men and 1,085 cases in women) are predicted to be identified in Australia in 2022. Also, as per same source, a person has a 1 in 111 (or 0.90%) chance of receiving a multiple myeloma analysis by the time they're 85 years vintage (1.1% for men and 0.74% for women). Thus, the predicted growth in people affected by multiple myeloma is expected to boost up the company’s recognition on developing effective and safe drugs. This is predicted to fuel the multiple myeloma market growth over the upcoming years.

Report Details:

The effectiveness of targeted medication options in the multiple myeloma industry has led to progressed outcomes in cancers cellular therapy and the creation of personalized treatment plans, leading to favorable outcomes for patients.

The myeloma market has increasingly desired targeted therapy as it can precisely targeted cancer cells without harming healthy cells, resulting in fewer side consequences and higher patient outcomes. Moreover, these medications may be tailored to a patient’s cancers type and genetic trends, for personalized treatment strategies. Another factor contributing to the dominance of targeted therapies in the multiple myeloma market is its effectiveness in treating multiple myeloma, with many targeted treatments displaying high response and improved survival costs in clinical trials. Finally, the approval of numerous new treatment treatments for multiple myeloma in current years has extended treatment options for patients, contributing to the boom and dominance of this market segment.

Female market percentage will grow quicker in the Multiple Myeloma market.

The upsurge in women patients in multiple myeloma market because of expanded awareness and early sickness prognosis amongst women, leading to higher detection and treatment. Moreover, as the populace grows, more women are developing multiple myeloma, and the threat of the disease will surge with age. The medical community is placing an elevated emphasis on research for multiple myeloma in women, that is leading to understanding of the disease and progressed therapies alternatives for female patients.

France's sturdy healthcare and favorable guidelines contributed to its growing epidemiology proportion in the Multiple Myeloma Market.

France's strong healthcare emphasizes cancers screening and early detection, resulting in the identification and reporting of multiple myeloma cases, which completed a significant percentage in the growth of France epidemiology multiple myeloma market. France also has a modern research and development infrastructure for cancers treatments that could result in better treatment results and longer survival costs for a multiple myeloma patient, attracting greater patients to are seeking for medication in France and contributing to the country's epidemiology share. In addition, France has favorable policies for clinical trials, which could appeal to pharmaceutical sector to conduct tests in France, leading to more revolutionary treatments and contributing to the country epidemiology proportion.

The United States has the most substantial share within the multiple myeloma market.

Due to the substantial numbers of humans tormented by multiple myeloma within the U.S., pharmaceutical companies see it as a viable marketplace to invest in and create new treatments. The American Cancer Society has anticipated that around 35,730 individuals will be identified with the ailment in 2023, and 12,590 deaths will result from it. Therefore, carrying out clinical trials and research on a larger patient populace can yield greater comprehensive data and evidence of treatment efficacy.

The United States boasts regulatory environment that encourages pharmaceutical agencies to conduct clinical trials and bring new drugs to market swiftly. Furthermore, a strong financial system creates a top of the line environment for funding in research and improvement, making it an appealing marketplace for stakeholders in the multiple myeloma industry.

Market Summary:

• Treatment Types – The Report covers the Multiple Myeloma Market by treatment types from 3 viewpoints (Targeted therapy, Chemotherapy, and Others).
• Gender share – The Multiple Myeloma Market, by gender share, breaks up into two viewpoints (Male and Female).
• Epidemiology Share – By Epidemiology share, the Multiple Myeloma Market is broken up into ten viewpoints (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Australia).
• Countries – By countries, the Multiple Myeloma Market breaks up into ten viewpoints (United States, United Kingdom, Germany, France, Spain, Italy, Japan, Australia, China, and Saudi Arabia).

About Us

Renub Research is a Market Research and Consulting Company. We have more than 14 years of experience especially in international Business-to-Business Researches, Surveys, and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. Our clients rely on our market analysis and data to make informed knowledgeable decisions. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.

Contact Us
Renub Research
Phone: +1-478-202-3244 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Web: https://www.renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research